{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:35:45Z","timestamp":1773797745726,"version":"3.50.1"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Moxifloxacin activity against\n            <jats:italic>Mycobacterium avium<\/jats:italic>\n            complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 \u03bcg\/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 \u03bcg\/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 \u03bcg\/ml and higher. To assess the activity of moxifloxacin containing regimens in vivo, we infected C57BL\n            <jats:italic>bg<\/jats:italic>\n            <jats:sup>+<\/jats:sup>\n            \/\n            <jats:italic>bg<\/jats:italic>\n            <jats:sup>+<\/jats:sup>\n            mice with 3 \u00d7 10\n            <jats:sup>7<\/jats:sup>\n            MAC strain 101 bacteria intravenously. One week later treatment was begun with the following: (i) moxifloxacin (50 mg\/kg\/day or 100 mg\/kg\/day), ethambutol (100 mg\/kg\/day), or a combination of moxifloxacin and ethambutol; or (ii) moxifloxacin (100 mg\/kg\/day), azithromycin (200 mg\/kg\/day), or rifabutin (40 mg\/kg\/day) as oral monotherapy; or (iii) all permutations of two-drug therapy or all three drugs in combination. All groups contained at least 14 animals, and the control group received the drug vehicle. After 4 weeks, quantitative blood cultures were obtained and the number of bacteria in liver and spleen was quantitated. Moxifloxacin, ethambutol, and azithromycin were active as single agents in liver, spleen, and blood. Rifabutin showed inhibitory activity only in the blood. Two-drug combinations containing azithromycin were no more active than azithromycin alone. Similarly, the three-drug combination was not more active than azithromycin alone in the spleen. Rifabutin did not add to the activity of any other single agent or two-drug combination. Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone.\n          <\/jats:p>","DOI":"10.1128\/aac.45.1.217-222.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"217-222","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against\n            <i>Mycobacterium avium<\/i>"],"prefix":"10.1128","volume":"45","author":[{"given":"Luiz E.","family":"Bermudez","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark B.","family":"Inderlied","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Children's Hospital of Los Angeles, University of Southern California, Los Angeles,2 California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kolonoski","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Petrofsky","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Aralar","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Children's Hospital of Los Angeles, University of Southern California, Los Angeles,2 California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wu","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lowell S.","family":"Young","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco,1 and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2717"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.546"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.1870"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.8.1844"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.180"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-12-199412150-00001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1164\/ajrccm\/137.1.149","article-title":"Pulmonary infection with nontuberculous mycobacteria.","volume":"137","author":"Contreras M. A.","year":"1988","unstructured":"Contreras M. A. Cheung O. T. Sanders D. E. Goldstein R. S. Pulmonary infection with nontuberculous mycobacteria. Am. Rev. Respir. Dis. 137 1988 149 152","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.8.1818"},{"key":"e_1_3_2_10_2","first-page":"219","article-title":"Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man.","volume":"50","author":"Freireich E. J.","year":"1996","unstructured":"Freireich E. J. Gehan E. A. Rall D. P. Schmidt L. H. Skipper H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep. 50 1996 219 244","journal-title":"Cancer Chemother. Rep."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/0003-4819-105-2-184","article-title":"Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome.","volume":"105","author":"Hawkins C. C.","year":"1986","unstructured":"Hawkins C. C. Gold J. W. Whimbey E. Kiehn T. E. Brannon P. Cammarata R. Brown A. E. Armstrong D. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 105 1986 184 188","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105093241906"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.6.3.266"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.11.1697"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/ajrccm\/144.4.914","article-title":"Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex.","volume":"144","author":"Iseman M. D.","year":"1991","unstructured":"Iseman M. D. Buschman D. L. Ackerson L. M. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am. Rev. Respir. Dis. 144 1991 914 916","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2066"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2521"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1341"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0041-3879(91)90004-C","article-title":"In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis.","volume":"72","author":"Ji B.","year":"1991","unstructured":"Ji B. Truffot-Pernot C. Grosset J. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 72 1991 181 186","journal-title":"Tubercle"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.85"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.12"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.976"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/43.suppl_2.69","article-title":"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species.","volume":"43","author":"Siefert H. M.","year":"1999","unstructured":"Siefert H. M. Domdey-Bette A. Henninger K. Hucke F. Kohlsdorfer C. Stass H. H. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J. Antimicrob. Chemother. 43 (Suppl. B) 1999 69 76","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jac\/43.suppl_2.61","article-title":"Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats.","volume":"43","author":"Siefert H. M.","year":"1999","unstructured":"Siefert H. M. Kohlsdorfer C. Steinke W. Witt A. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J. Antimicrob. Chemother. 43 (Suppl. B) 1999 61 67","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2060"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.1.217-222.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.1.217-222.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:03:24Z","timestamp":1645463004000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.1.217-222.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1128\/AAC.45.1.217-222.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.1.217-222.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]},"assertion":[{"value":"2000-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}